Skip to main content

FDA Inspections & Warning Letters

US-unique

FDA's direct inspection authority over device manufacturers (domestic and foreign) — and the warning letter system — are distinctly US mechanisms. FDA can inspect without advance notice (announced or unannounced).

Types of FDA device inspections

Inspection typeDescription
Surveillance inspectionRoutine inspection of registered establishment; periodic (typically every 2 years for Class II/III)
Compliance follow-upAfter a previous inspection with observations — checks for corrective actions
Pre-approval inspection (PAI)Before FDA approves a PMA; verifies manufacturing processes and data integrity
For-cause inspectionTriggered by complaints, MDR trends, or recall activities
Unannounced inspectionFDA investigators may arrive without advance notice for domestic manufacturers

What FDA investigators examine

  • QMSR compliance — design controls, CAPA, complaint handling, MDR procedures
  • Document and record integrity — are records complete, accurate, and retrievable?
  • Manufacturing practices — cleanliness, controlled processes, calibration, environmental monitoring
  • Complaint files — are complaints reviewed for MDR reportability?
  • Corrective actions — response to previous observations

FDA Form 483 — Inspectional Observations

At the end of an inspection, the FDA investigator may issue FDA Form 483 — a list of observed conditions that may constitute violations. A 483 is not a final determination of violation — it is an observation that the manufacturer must respond to.

Response to 483:

  • Respond in writing within 15 business days (longer if needed for complex issues)
  • Acknowledge each observation
  • Provide specific corrective actions with timelines
  • Provide evidence of completed corrections where available

Official resources